{"protocolSection": {"identificationModule": {"nctId": "NCT00200967", "orgStudyIdInfo": {"id": "262"}, "secondaryIdInfos": [{"id": "5U10HL074231", "type": "NIH", "link": "https://reporter.nih.gov/quickSearch/5U10HL074231"}, {"id": "U10HL074073", "type": "NIH", "link": "https://reporter.nih.gov/quickSearch/U10HL074073"}, {"id": "U10HL074204", "type": "NIH", "link": "https://reporter.nih.gov/quickSearch/U10HL074204"}, {"id": "U10HL074208", "type": "NIH", "link": "https://reporter.nih.gov/quickSearch/U10HL074208"}, {"id": "U10HL074212", "type": "NIH", "link": "https://reporter.nih.gov/quickSearch/U10HL074212"}, {"id": "U10HL074218", "type": "NIH", "link": "https://reporter.nih.gov/quickSearch/U10HL074218"}, {"id": "U10HL074225", "type": "NIH", "link": "https://reporter.nih.gov/quickSearch/U10HL074225"}, {"id": "U10HL074227", "type": "NIH", "link": "https://reporter.nih.gov/quickSearch/U10HL074227"}, {"id": "U10HL074231", "type": "NIH", "link": "https://reporter.nih.gov/quickSearch/U10HL074231"}], "organization": {"fullName": "Milton S. Hershey Medical Center", "class": "OTHER"}, "briefTitle": "Asthma Clinical Research Network (ACRN) Trial - Long-Acting Beta Agonist Response by Genotype (LARGE)", "officialTitle": "Asthma Clinical Research Network (ACRN) Trial - Long-Acting Beta Agonist Response by Genotype (LARGE)"}, "statusModule": {"statusVerifiedDate": "2017-12", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2004-12"}, "primaryCompletionDateStruct": {"date": "2008-02", "type": "ACTUAL"}, "completionDateStruct": {"date": "2008-02", "type": "ACTUAL"}, "studyFirstSubmitDate": "2005-09-12", "studyFirstSubmitQcDate": "2005-09-12", "studyFirstPostDateStruct": {"date": "2005-09-20", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2009-03-05", "resultsFirstSubmitQcDate": "2009-04-08", "resultsFirstPostDateStruct": {"date": "2009-06-02", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2017-12-26", "lastUpdatePostDateStruct": {"date": "2018-01-23", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Vernon M. Chinchilli, PhD", "investigatorTitle": "Professor and Chair, Department of Public Health Sciences", "investigatorAffiliation": "Milton S. Hershey Medical Center"}, "leadSponsor": {"name": "Milton S. Hershey Medical Center", "class": "OTHER"}, "collaborators": [{"name": "National Heart, Lung, and Blood Institute (NHLBI)", "class": "NIH"}, {"name": "Asthma Clinical Research Network", "class": "NETWORK"}]}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "The purpose of this trial is to determine whether regularly scheduled use of an inhaled long-acting beta agonist (salmeterol) in the setting of concomitant use of inhaled corticosteroids (beclomethasone hydroflouroalkane (HFA) inhaler) will have a detrimental effect on asthma control in people who bear the B16-Arg/Arg genotype of the beta-2 adrenergic receptor gene, as compared to people with asthma of similar severity who bear the B16-Gly/Gly genotype.", "detailedDescription": "BACKGROUND:\n\nThe purpose of this study is to compare the effects of a long-acting beta agonist in patients with asthma receiving inhaled corticosteroids who express two distinct polymorphisms of the beta-2 adrenergic receptor.\n\nDESIGN NARRATIVE:\n\nParticipants were homozygous for arginine or glycine at the 16th amino-acid position of the \u03b2-2 adrenergic receptor (B16 Arg/Arg or B16 Gly/Gly). Individuals were matched against their opposite genotype by forced expiratory volume in one second (FEV1) and race. Matched participants entered an 8-week run-in period. This is a 62-week crossover design where subjects receive the following therapies:\n\n* Beclomethasone HFA (240 \u00b5g twice a day (BID)) + as-needed (PRN) albuterol: 8-week run-in\n* Beclomethasone HFA (240 \u00b5g BID) + salmeterol (50 \u00b5g BID) + PRN ipratropium bromide + PRN albuterol: 18-week treatment period\n* Beclomethasone HFA (240 \u00b5g BID) + PRN albuterol: 8-week run-out\n* Beclomethasone HFA (240 \u00b5g BID) + placebo salmeterol + PRN ipratropium bromide + PRN albuterol: 18-week treatment period\n* Beclomethasone HFA (240 \u00b5g BID) + PRN albuterol: 10-week run-out\n\nThe order of treatments received during the two treatment periods is randomized."}, "conditionsModule": {"conditions": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 87, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "B16 Arg/Arg", "type": "EXPERIMENTAL", "description": "B16 Arg/Arg genotype Sequence 1: inhaled salmeterol + inhaled beclomethasone hydroflouroalkane (HFA), followed by inhaled placebo salmeterol + inhaled beclomethasone HFA Sequence 2: inhaled placebo salmeterol + inhaled beclomethasone HFA, followed by inhaled salmeterol + inhaled beclomethasone HFA", "interventionNames": ["Drug: salmeterol", "Drug: beclomethasone HFA"]}, {"label": "B16 Gly/Gly", "type": "EXPERIMENTAL", "description": "B16 Gly/Gly genotype Sequence 1: inhaled salmeterol + inhaled beclomethasone HFA, followed by inhaled placebo salmeterol + inhaled beclomethasone HFA Sequence 2: inhaled placebo salmeterol + inhaled beclomethasone HFA, followed by inhaled salmeterol + inhaled beclomethasone HFA", "interventionNames": ["Drug: salmeterol", "Drug: beclomethasone HFA"]}], "interventions": [{"type": "DRUG", "name": "salmeterol", "description": "50 micrograms (mcg) twice per day (BID) (Serevent 50 mcg diskus, GlaxoSmithKline (GSK), North Carolina)", "armGroupLabels": ["B16 Arg/Arg", "B16 Gly/Gly"], "otherNames": ["Serevent"]}, {"type": "DRUG", "name": "beclomethasone HFA", "description": "240 mcg beclomethasone HFA (QVAR, Teva Pharmaceutical Industries)", "armGroupLabels": ["B16 Arg/Arg", "B16 Gly/Gly"], "otherNames": ["QVAR"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Morning (AM) Peak Expiratory Flow (PEF) Rate", "description": "Change between placebo salmeterol and active salmeterol for AM PEF rate", "timeFrame": "Measured daily using a hand-held peak flow meter, and then averaged between weeks 0, 2, 6, 10, 14, and 18 of each treatment period"}], "secondaryOutcomes": [{"measure": "Evening (PM) Peak Expiratory Flow (PEF) Rate", "description": "Change between placebo salmeterol and active salmeterol for PM PEF rate", "timeFrame": "Measured daily using a hand-held peak flow meter, and then averaged between weeks 0, 2, 6, 10, 14, and 18 of each treatment period"}, {"measure": "Peak Expiratory Flow (PEF) Variability", "description": "Change between placebo salmeterol and active salmeterol for PEF variability, where PEF variability is defined as 100% x (PM PEF - AM PEF)/(PM PEF)", "timeFrame": "Measured daily using a hand-held peak flow meter, and then averaged between weeks 0, 2, 6, 10, 14, and 18 of each treatment period"}, {"measure": "Asthma Symptoms", "description": "Change between placebo salmeterol and active salmeterol for asthma symptoms (0=absent, 1=mild, 2=moderate, 3=severe).", "timeFrame": "Recorded daily on a diary card, and then averaged between weeks 0, 2, 6, 10, 14, and 18 of each treatment period"}, {"measure": "Rescue Medication (Ipratropium and Albuterol) Use", "description": "Change between placebo salmeterol and active salmeterol for rescue medication use", "timeFrame": "Recorded daily on a diary card, and then averaged between weeks 0, 2, 6, 10, 14, and 18 of each treatment period"}, {"measure": "Spirometry Forced Expiratory Volume in One Second (FEV1), Pre-bronchodilator", "description": "Change between placebo salmeterol and active salmeterol for Spirometry FEV1, pre-bronchodilator", "timeFrame": "Clinic visits at weeks 0, 2, 6, 10, 14, and 18 of each treatment period"}, {"measure": "Spirometry Forced Vital Capacity (FVC), Pre-bronchodilator", "description": "Change between placebo salmeterol and active salmeterol for Spirometry FVC, pre-bronchodilator", "timeFrame": "Clinic visits at weeks 0, 2, 6, 10, 14, and 18 of each treatment period"}, {"measure": "Spirometry Peak Expiratory Flow (PEF) Rate, Pre-bronchodilator", "description": "Change between placebo salmeterol and active salmeterol for Spirometry PEF rate, pre-bronchodilator", "timeFrame": "Clinic visits at weeks 0, 2, 6, 10, 14, and 18 of each treatment period"}, {"measure": "Exhaled Nitric Oxide (eNO)", "description": "Change between placebo salmeterol and active salmeterol for eNO", "timeFrame": "Clinic visits at weeks 0, 2, 6, 10, 14, and 18 of each treatment period"}, {"measure": "Exhaled Breath Condensate (EBC)", "description": "Change between placebo salmeterol and active salmeterol for EBC", "timeFrame": "Clinic visits at weeks 0, 10, and 18 of each treatment period"}, {"measure": "Methacholine Provocative Concentration 20 (PC20)", "description": "Change between placebo salmeterol and active salmeterol for methacholine PC20", "timeFrame": "Clinic visits at weeks 0 and 18 of each treatment period"}, {"measure": "Asthma Control Questionnaire (ACQ)", "description": "Change between placebo salmeterol and active salmeterol for ACQ, where ACQ ranges from 0 (best asthma control) to 6 (worst asthma control).", "timeFrame": "Clinic visits at weeks 0 and 18 of each treatment period"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Male or female, ages 18 and older\n* Clinical history consistent with asthma\n* For subjects regularly using inhaled corticosteroids, FEV1 50% of predicted, methacholine PC20 FEV1 16 mg/ml or 12% and 200 ml, improvement in FEV1 after 2 puffs of inhaled albuterol\n* For subjects not regularly using inhaled corticosteroids, FEV1 40% of predicted, methacholine PC20 FEV1 8 mg/ml or 12% and 200 ml, improvement in FEV1 after 2 puffs of inhaled albuterol\n* Genotype eligibility (determined during screening)\n\nExclusion Criteria:\n\n* Smoker (total smoking history must be less than 10 pack years)\n* Significant unstable medical condition other than asthma\n* History of life-threatening asthma requiring treatment with intubation and mechanical ventilation in the past 10 years\n* Pregnant or lactating", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "90 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Homer Boushey", "affiliation": "University of California, San Francisco", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Mario Castro", "affiliation": "Washington University School of Medicine", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Vernon M. Chinchilli, PhD", "affiliation": "Milton S. Hershey Medical Center", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Elliot Israel", "affiliation": "Brigham and Women's Hospital", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Robert Lemanske", "affiliation": "University of Wisconsin, Madison", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Richard Martin", "affiliation": "National Jewish Medical & Research Center", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Stephen Peters", "affiliation": "Wake Forest University Health Sciences", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Stephen Wasserman", "affiliation": "University of California, San Diego", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "University of California, San Diego", "city": "San Diego", "state": "California", "zip": "92103", "country": "United States", "geoPoint": {"lat": 32.71533, "lon": -117.15726}}, {"facility": "University of California, San Francisco", "city": "San Francisco", "state": "California", "zip": "94143-0130", "country": "United States", "geoPoint": {"lat": 37.77493, "lon": -122.41942}}, {"facility": "National Jewish Medical & Research Center", "city": "Denver", "state": "Colorado", "zip": "80206", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"facility": "Brigham & Women's Hospital", "city": "Boston", "state": "Massachusetts", "zip": "02115", "country": "United States", "geoPoint": {"lat": 42.35843, "lon": -71.05977}}, {"facility": "Washington University", "city": "Saint Louis", "state": "Missouri", "zip": "63110", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Wake Forest University Health Sciences", "city": "Winston-Salem", "state": "North Carolina", "zip": "27103", "country": "United States", "geoPoint": {"lat": 36.09986, "lon": -80.24422}}, {"facility": "University of Wisconsin Madison", "city": "Madison", "state": "Wisconsin", "zip": "53792-3244", "country": "United States", "geoPoint": {"lat": 43.07305, "lon": -89.40123}}]}, "referencesModule": {"references": [{"pmid": "19932356", "type": "RESULT", "citation": "Wechsler ME, Kunselman SJ, Chinchilli VM, Bleecker E, Boushey HA, Calhoun WJ, Ameredes BT, Castro M, Craig TJ, Denlinger L, Fahy JV, Jarjour N, Kazani S, Kim S, Kraft M, Lazarus SC, Lemanske RF Jr, Markezich A, Martin RJ, Permaul P, Peters SP, Ramsdell J, Sorkness CA, Sutherland ER, Szefler SJ, Walter MJ, Wasserman SI, Israel E; National Heart, Lung and Blood Institute's Asthma Clinical Research Network. Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial. Lancet. 2009 Nov 21;374(9703):1754-64. doi: 10.1016/S0140-6736(09)61492-6."}], "seeAlsoLinks": [{"label": "Asthma Clinical Research Network (ACRN) Website", "url": "http://www.acrn.org"}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "474 participants were screened: 78 had B16 Arg/Arg genotype; 166 had B16 Gly/Gly genotype; 230 had Arg/Gly genotype. 47 matched Arg/Arg-Gly/Gly pairs entered the 8-week run-in period. 42 Arg/Arg were randomized (2 withdrew, 2 noncompliant, 1 lost); 45 Gly/Gly were randomized (1 withdrew, 1 noncompliant).", "recruitmentDetails": "Recruitment for the LARGE trial began in November 2004 and the final participant visits occurred in February 2008. Seven academic medical centers throughout the US recruited the participants.", "groups": [{"id": "FG000", "title": "B16 Arg/Arg", "description": "B16 Arg/Arg genotype Sequence 1: inhaled salmeterol + inhaled beclomethasone HFA, followed by inhaled placebo salmeterol + inhaled beclomethasone HFA Sequence 2: inhaled placebo salmeterol + inhaled beclomethasone HFA, followed by inhaled salmeterol + inhaled beclomethasone HFA"}, {"id": "FG001", "title": "B16 Gly/Gly", "description": "B16 Arg/Arg genotype Sequence 1: inhaled salmeterol + inhaled beclomethasone HFA, followed by inhaled placebo salmeterol + inhaled beclomethasone HFA Sequence 2: inhaled placebo salmeterol + inhaled beclomethasone HFA, followed by inhaled salmeterol + inhaled beclomethasone HFA"}], "periods": [{"title": "First Treatment Period", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "42"}, {"groupId": "FG001", "numSubjects": "45"}]}, {"type": "First Treatment Period", "achievements": [{"groupId": "FG000", "numSubjects": "42"}, {"groupId": "FG001", "numSubjects": "45"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "36"}, {"groupId": "FG001", "numSubjects": "44"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Pregnancy", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}]}, {"title": "Wash-out Period", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "36"}, {"groupId": "FG001", "numSubjects": "44"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "36"}, {"groupId": "FG001", "numSubjects": "43"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}]}, {"title": "Second Treatment Period", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "36"}, {"groupId": "FG001", "numSubjects": "43"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "35"}, {"groupId": "FG001", "numSubjects": "41"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "2"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "2"}]}]}, {"title": "Run-out Period", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "35"}, {"groupId": "FG001", "numSubjects": "41"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "34"}, {"groupId": "FG001", "numSubjects": "41"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "B16 Arg/Arg", "description": "B16 Arg/Arg genotype Sequence 1: inhaled salmeterol + inhaled beclomethasone HFA, followed by inhaled placebo salmeterol + inhaled beclomethasone HFA Sequence 2: inhaled placebo salmeterol + inhaled beclomethasone HFA, followed by inhaled salmeterol + inhaled beclomethasone HFA"}, {"id": "BG001", "title": "B16 Gly/Gly", "description": "B16 Arg/Arg genotype Sequence 1: inhaled salmeterol + inhaled beclomethasone HFA, followed by inhaled placebo salmeterol + inhaled beclomethasone HFA Sequence 2: inhaled placebo salmeterol + inhaled beclomethasone HFA, followed by inhaled salmeterol + inhaled beclomethasone HFA"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "42"}, {"groupId": "BG001", "value": "45"}, {"groupId": "BG002", "value": "87"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "42"}, {"groupId": "BG001", "value": "45"}, {"groupId": "BG002", "value": "87"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "39", "spread": "11"}, {"groupId": "BG001", "value": "42", "spread": "12"}, {"groupId": "BG002", "value": "41", "spread": "12"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "32"}, {"groupId": "BG001", "value": "29"}, {"groupId": "BG002", "value": "61"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "10"}, {"groupId": "BG001", "value": "16"}, {"groupId": "BG002", "value": "26"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "42"}, {"groupId": "BG001", "value": "45"}, {"groupId": "BG002", "value": "87.0"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Morning (AM) Peak Expiratory Flow (PEF) Rate", "description": "Change between placebo salmeterol and active salmeterol for AM PEF rate", "populationDescription": "An intention-to-treat (ITT) paradigm was invoked in which the available data (without any imputation for missing data) on all randomized participants were included.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "liters per minute", "timeFrame": "Measured daily using a hand-held peak flow meter, and then averaged between weeks 0, 2, 6, 10, 14, and 18 of each treatment period", "groups": [{"id": "OG000", "title": "B16 Arg/Arg", "description": "B16 Arg/Arg genotype Sequence 1: inhaled salmeterol + inhaled beclomethasone HFA, followed by inhaled placebo salmeterol + inhaled beclomethasone HFA Sequence 2: inhaled placebo salmeterol + inhaled beclomethasone HFA, followed by inhaled salmeterol + inhaled beclomethasone HFA"}, {"id": "OG001", "title": "B16 Gly/Gly", "description": "B16 Arg/Arg genotype Sequence 1: inhaled salmeterol + inhaled beclomethasone HFA, followed by inhaled placebo salmeterol + inhaled beclomethasone HFA Sequence 2: inhaled placebo salmeterol + inhaled beclomethasone HFA, followed by inhaled salmeterol + inhaled beclomethasone HFA"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "42"}, {"groupId": "OG001", "value": "45"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-21", "lowerLimit": "-31", "upperLimit": "-12"}, {"groupId": "OG001", "value": "-22", "lowerLimit": "-32", "upperLimit": "-11"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "A mixed-effects linear model was applied to account for the repeated measurements within each treatment period of the crossover design. A sample size of 40 participants per genotype was required to detect a difference of 25 L/min in AM PEF (and relevant effect sizes for secondary outcomes) with a two-sided, 0.05 significance level test with 90% statistical power and a 15% drop-out rate.", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.99", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "0", "ciPctValue": "95", "ciLowerLimit": "-14", "ciUpperLimit": "14", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "7", "estimateComment": "The comparison represents the difference between Arg/Arg and Gly/Gly participants based on the change between placebo salmeterol and active salmeterol for AM PEF rate."}]}, {"type": "SECONDARY", "title": "Evening (PM) Peak Expiratory Flow (PEF) Rate", "description": "Change between placebo salmeterol and active salmeterol for PM PEF rate", "populationDescription": "An ITT paradigm was invoked in which the available data (without any imputation for missing data) on all randomized participants were included.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "liters per minute", "timeFrame": "Measured daily using a hand-held peak flow meter, and then averaged between weeks 0, 2, 6, 10, 14, and 18 of each treatment period", "groups": [{"id": "OG000", "title": "B16 Arg/Arg", "description": "B16 Arg/Arg genotype Sequence 1: inhaled salmeterol + inhaled beclomethasone HFA, followed by inhaled placebo salmeterol + inhaled beclomethasone HFA Sequence 2: inhaled placebo salmeterol + inhaled beclomethasone HFA, followed by inhaled salmeterol + inhaled beclomethasone HFA"}, {"id": "OG001", "title": "B16 Gly/Gly", "description": "B16 Arg/Arg genotype Sequence 1: inhaled salmeterol + inhaled beclomethasone HFA, followed by inhaled placebo salmeterol + inhaled beclomethasone HFA Sequence 2: inhaled placebo salmeterol + inhaled beclomethasone HFA, followed by inhaled salmeterol + inhaled beclomethasone HFA"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "42"}, {"groupId": "OG001", "value": "45"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-25", "lowerLimit": "-34", "upperLimit": "-16"}, {"groupId": "OG001", "value": "-24", "lowerLimit": "-34", "upperLimit": "-14"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "A mixed-effects linear model was applied to account for the repeated measurements within each treatment period of the crossover design.", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.82", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-1", "ciPctValue": "95", "ciLowerLimit": "-15", "ciUpperLimit": "12", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "7", "estimateComment": "The comparison represents the difference between Arg/Arg and Gly/Gly participants based on the change between placebo salmeterol and active salmeterol for PM PEF rate."}]}, {"type": "SECONDARY", "title": "Peak Expiratory Flow (PEF) Variability", "description": "Change between placebo salmeterol and active salmeterol for PEF variability, where PEF variability is defined as 100% x (PM PEF - AM PEF)/(PM PEF)", "populationDescription": "An ITT paradigm was invoked in which the available data (without any imputation for missing data) on all randomized participants were included.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "percentage", "timeFrame": "Measured daily using a hand-held peak flow meter, and then averaged between weeks 0, 2, 6, 10, 14, and 18 of each treatment period", "groups": [{"id": "OG000", "title": "B16 Arg/Arg", "description": "B16 Arg/Arg genotype Sequence 1: inhaled salmeterol + inhaled beclomethasone HFA, followed by inhaled placebo salmeterol + inhaled beclomethasone HFA Sequence 2: inhaled placebo salmeterol + inhaled beclomethasone HFA, followed by inhaled salmeterol + inhaled beclomethasone HFA"}, {"id": "OG001", "title": "B16 Gly/Gly", "description": "B16 Arg/Arg genotype Sequence 1: inhaled salmeterol + inhaled beclomethasone HFA, followed by inhaled placebo salmeterol + inhaled beclomethasone HFA Sequence 2: inhaled placebo salmeterol + inhaled beclomethasone HFA, followed by inhaled salmeterol + inhaled beclomethasone HFA"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "42"}, {"groupId": "OG001", "value": "45"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.2", "lowerLimit": "-0.6", "upperLimit": "1.0"}, {"groupId": "OG001", "value": "0.7", "lowerLimit": "0.0", "upperLimit": "1.4"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "A mixed-effects linear model was applied to account for the repeated measurements within each treatment period of the crossover design.", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.31", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.6", "ciPctValue": "95", "ciLowerLimit": "-1.6", "ciUpperLimit": "0.5", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.5", "estimateComment": "The comparison represents the difference between Arg/Arg and Gly/Gly participants based on the change between placebo salmeterol and active salmeterol for PEF variability."}]}, {"type": "SECONDARY", "title": "Asthma Symptoms", "description": "Change between placebo salmeterol and active salmeterol for asthma symptoms (0=absent, 1=mild, 2=moderate, 3=severe).", "populationDescription": "An ITT paradigm was invoked in which the available data (without any imputation for missing data) on all randomized participants were included.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "units on a scale", "timeFrame": "Recorded daily on a diary card, and then averaged between weeks 0, 2, 6, 10, 14, and 18 of each treatment period", "groups": [{"id": "OG000", "title": "B16 Arg/Arg", "description": "B16 Arg/Arg genotype Sequence 1: inhaled salmeterol + inhaled beclomethasone HFA, followed by inhaled placebo salmeterol + inhaled beclomethasone HFA Sequence 2: inhaled placebo salmeterol + inhaled beclomethasone HFA, followed by inhaled salmeterol + inhaled beclomethasone HFA"}, {"id": "OG001", "title": "B16 Gly/Gly", "description": "B16 Arg/Arg genotype Sequence 1: inhaled salmeterol + inhaled beclomethasone HFA, followed by inhaled placebo salmeterol + inhaled beclomethasone HFA Sequence 2: inhaled placebo salmeterol + inhaled beclomethasone HFA, followed by inhaled salmeterol + inhaled beclomethasone HFA"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "42"}, {"groupId": "OG001", "value": "45"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.04", "lowerLimit": "0.00", "upperLimit": "0.12"}, {"groupId": "OG001", "value": "0.00", "lowerLimit": "-0.01", "upperLimit": "0.02"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "A mixed-effects linear model was attempted but could not converge because very few symptoms were recorded, so a nonparametric analysis was applied.", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.09", "statisticalMethod": "Wilcoxon (Mann-Whitney)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.02", "ciPctValue": "95", "ciLowerLimit": "-0.02", "ciUpperLimit": "0.07", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.02", "estimateComment": "The comparison represents the difference between Arg/Arg and Gly/Gly participants based on the change between placebo salmeterol and active salmeterol for asthma symptoms."}]}, {"type": "SECONDARY", "title": "Rescue Medication (Ipratropium and Albuterol) Use", "description": "Change between placebo salmeterol and active salmeterol for rescue medication use", "populationDescription": "An ITT paradigm was invoked in which the available data (without any imputation for missing data) on all randomized participants were included.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "puffs per day", "timeFrame": "Recorded daily on a diary card, and then averaged between weeks 0, 2, 6, 10, 14, and 18 of each treatment period", "groups": [{"id": "OG000", "title": "B16 Arg/Arg", "description": "B16 Arg/Arg genotype Sequence 1: inhaled salmeterol + inhaled beclomethasone HFA, followed by inhaled placebo salmeterol + inhaled beclomethasone HFA Sequence 2: inhaled placebo salmeterol + inhaled beclomethasone HFA, followed by inhaled salmeterol + inhaled beclomethasone HFA"}, {"id": "OG001", "title": "B16 Gly/Gly", "description": "B16 Arg/Arg genotype Sequence 1: inhaled salmeterol + inhaled beclomethasone HFA, followed by inhaled placebo salmeterol + inhaled beclomethasone HFA Sequence 2: inhaled placebo salmeterol + inhaled beclomethasone HFA, followed by inhaled salmeterol + inhaled beclomethasone HFA"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "42"}, {"groupId": "OG001", "value": "45"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.2", "lowerLimit": "0.0", "upperLimit": "0.5"}, {"groupId": "OG001", "value": "0.0", "lowerLimit": "0.0", "upperLimit": "0.2"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "A mixed-effects linear model was attempted but could not converge because very few usages of rescue medications were recorded, so a nonparametric analysis was applied.", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.25", "statisticalMethod": "Wilcoxon (Mann-Whitney)", "paramType": "Mean Difference (Final Values)", "paramValue": "0.0", "ciPctValue": "95", "ciLowerLimit": "-0.1", "ciUpperLimit": "0.2", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.1", "estimateComment": "The comparison represents the difference between Arg/Arg and Gly/Gly participants based on the change between placebo salmeterol and active salmeterol for rescue medication use."}]}, {"type": "SECONDARY", "title": "Spirometry Forced Expiratory Volume in One Second (FEV1), Pre-bronchodilator", "description": "Change between placebo salmeterol and active salmeterol for Spirometry FEV1, pre-bronchodilator", "populationDescription": "An ITT paradigm was invoked in which the available data (without any imputation for missing data) on all randomized participants were included.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "liters", "timeFrame": "Clinic visits at weeks 0, 2, 6, 10, 14, and 18 of each treatment period", "groups": [{"id": "OG000", "title": "B16 Arg/Arg", "description": "B16 Arg/Arg genotype Sequence 1: inhaled salmeterol + inhaled beclomethasone HFA, followed by inhaled placebo salmeterol + inhaled beclomethasone HFA Sequence 2: inhaled placebo salmeterol + inhaled beclomethasone HFA, followed by inhaled salmeterol + inhaled beclomethasone HFA"}, {"id": "OG001", "title": "B16 Gly/Gly", "description": "B16 Arg/Arg genotype Sequence 1: inhaled salmeterol + inhaled beclomethasone HFA, followed by inhaled placebo salmeterol + inhaled beclomethasone HFA Sequence 2: inhaled placebo salmeterol + inhaled beclomethasone HFA, followed by inhaled salmeterol + inhaled beclomethasone HFA"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "42"}, {"groupId": "OG001", "value": "45"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.08", "lowerLimit": "-0.13", "upperLimit": "-0.03"}, {"groupId": "OG001", "value": "-0.04", "lowerLimit": "-0.09", "upperLimit": "0.00"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "A mixed-effects linear model was applied to account for the repeated measurements within each treatment period of the crossover design.", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.34", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.03", "ciPctValue": "95", "ciLowerLimit": "-0.10", "ciUpperLimit": "0.03", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.03", "estimateComment": "The comparison represents the difference between Arg/Arg and Gly/Gly participants based on the change between placebo salmeterol and active salmeterol for Spirometry FEV1, pre-bronchodilator."}]}, {"type": "SECONDARY", "title": "Spirometry Forced Vital Capacity (FVC), Pre-bronchodilator", "description": "Change between placebo salmeterol and active salmeterol for Spirometry FVC, pre-bronchodilator", "populationDescription": "An ITT paradigm was invoked in which the available data (without any imputation for missing data) on all randomized participants were included.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "liters", "timeFrame": "Clinic visits at weeks 0, 2, 6, 10, 14, and 18 of each treatment period", "groups": [{"id": "OG000", "title": "B16 Arg/Arg", "description": "B16 Arg/Arg genotype Sequence 1: inhaled salmeterol + inhaled beclomethasone HFA, followed by inhaled placebo salmeterol + inhaled beclomethasone HFA Sequence 2: inhaled placebo salmeterol + inhaled beclomethasone HFA, followed by inhaled salmeterol + inhaled beclomethasone HFA"}, {"id": "OG001", "title": "B16 Gly/Gly", "description": "B16 Arg/Arg genotype Sequence 1: inhaled salmeterol + inhaled beclomethasone HFA, followed by inhaled placebo salmeterol + inhaled beclomethasone HFA Sequence 2: inhaled placebo salmeterol + inhaled beclomethasone HFA, followed by inhaled salmeterol + inhaled beclomethasone HFA"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "42"}, {"groupId": "OG001", "value": "45"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.04", "lowerLimit": "-0.08", "upperLimit": "0.01"}, {"groupId": "OG001", "value": "-0.03", "lowerLimit": "-0.09", "upperLimit": "0.03"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "A mixed-effects linear model was applied to account for the repeated measurements within each treatment period of the crossover design.", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.91", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "0.00", "ciPctValue": "95", "ciLowerLimit": "-0.08", "ciUpperLimit": "0.07", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.03", "estimateComment": "The comparison represents the difference between Arg/Arg and Gly/Gly participants based on the change between placebo salmeterol and active salmeterol for Spirometry FVC, pre-bronchodilator."}]}, {"type": "SECONDARY", "title": "Spirometry Peak Expiratory Flow (PEF) Rate, Pre-bronchodilator", "description": "Change between placebo salmeterol and active salmeterol for Spirometry PEF rate, pre-bronchodilator", "populationDescription": "An ITT paradigm was invoked in which the available data (without any imputation for missing data) on all randomized participants were included.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "liters per minute", "timeFrame": "Clinic visits at weeks 0, 2, 6, 10, 14, and 18 of each treatment period", "groups": [{"id": "OG000", "title": "B16 Arg/Arg", "description": "B16 Arg/Arg genotype Sequence 1: inhaled salmeterol + inhaled beclomethasone HFA, followed by inhaled placebo salmeterol + inhaled beclomethasone HFA Sequence 2: inhaled placebo salmeterol + inhaled beclomethasone HFA, followed by inhaled salmeterol + inhaled beclomethasone HFA"}, {"id": "OG001", "title": "B16 Gly/Gly", "description": "B16 Arg/Arg genotype Sequence 1: inhaled salmeterol + inhaled beclomethasone HFA, followed by inhaled placebo salmeterol + inhaled beclomethasone HFA Sequence 2: inhaled placebo salmeterol + inhaled beclomethasone HFA, followed by inhaled salmeterol + inhaled beclomethasone HFA"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "42"}, {"groupId": "OG001", "value": "45"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-17", "lowerLimit": "-27", "upperLimit": "-8"}, {"groupId": "OG001", "value": "-17", "lowerLimit": "-27", "upperLimit": "-6"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "A mixed-effects linear model was applied to account for the repeated measurements within each treatment period of the crossover design.", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.93", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-1", "ciPctValue": "95", "ciLowerLimit": "-15", "ciUpperLimit": "14", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "7", "estimateComment": "The comparison represents the difference between Arg/Arg and Gly/Gly participants based on the change between placebo salmeterol and active salmeterol for Spirometry PEF rate, pre-bronchodilator."}]}, {"type": "SECONDARY", "title": "Exhaled Nitric Oxide (eNO)", "description": "Change between placebo salmeterol and active salmeterol for eNO", "populationDescription": "An ITT paradigm was invoked in which the available data (without any imputation for missing data) on all randomized participants were included.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "parts per billion", "timeFrame": "Clinic visits at weeks 0, 2, 6, 10, 14, and 18 of each treatment period", "groups": [{"id": "OG000", "title": "B16 Arg/Arg", "description": "B16 Arg/Arg genotype Sequence 1: inhaled salmeterol + inhaled beclomethasone HFA, followed by inhaled placebo salmeterol + inhaled beclomethasone HFA Sequence 2: inhaled placebo salmeterol + inhaled beclomethasone HFA, followed by inhaled salmeterol + inhaled beclomethasone HFA"}, {"id": "OG001", "title": "B16 Gly/Gly", "description": "B16 Arg/Arg genotype Sequence 1: inhaled salmeterol + inhaled beclomethasone HFA, followed by inhaled placebo salmeterol + inhaled beclomethasone HFA Sequence 2: inhaled placebo salmeterol + inhaled beclomethasone HFA, followed by inhaled salmeterol + inhaled beclomethasone HFA"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "42"}, {"groupId": "OG001", "value": "45"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.12", "lowerLimit": "-0.01", "upperLimit": "0.24"}, {"groupId": "OG001", "value": "-0.02", "lowerLimit": "-0.15", "upperLimit": "0.11"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "A mixed-effects linear model was applied to the natural logarithm of eNO to account for the repeated measurements within each treatment period of the crossover design.", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.13", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "0.14", "ciPctValue": "95", "ciLowerLimit": "-0.04", "ciUpperLimit": "0.31", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.08", "estimateComment": "The comparison represents the difference between Arg/Arg and Gly/Gly participants based on the change between placebo salmeterol and active salmeterol for eNO."}]}, {"type": "SECONDARY", "title": "Exhaled Breath Condensate (EBC)", "description": "Change between placebo salmeterol and active salmeterol for EBC", "populationDescription": "An ITT paradigm was invoked in which the available data (without any imputation for missing data) on all randomized participants were included.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "pH", "timeFrame": "Clinic visits at weeks 0, 10, and 18 of each treatment period", "groups": [{"id": "OG000", "title": "B16 Arg/Arg", "description": "B16 Arg/Arg genotype Sequence 1: inhaled salmeterol + inhaled beclomethasone HFA, followed by inhaled placebo salmeterol + inhaled beclomethasone HFA Sequence 2: inhaled placebo salmeterol + inhaled beclomethasone HFA, followed by inhaled salmeterol + inhaled beclomethasone HFA"}, {"id": "OG001", "title": "B16 Gly/Gly", "description": "B16 Arg/Arg genotype Sequence 1: inhaled salmeterol + inhaled beclomethasone HFA, followed by inhaled placebo salmeterol + inhaled beclomethasone HFA Sequence 2: inhaled placebo salmeterol + inhaled beclomethasone HFA, followed by inhaled salmeterol + inhaled beclomethasone HFA"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "42"}, {"groupId": "OG001", "value": "45"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.10", "lowerLimit": "-0.45", "upperLimit": "0.26"}, {"groupId": "OG001", "value": "-0.03", "lowerLimit": "-0.37", "upperLimit": "0.31"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "A mixed-effects linear model was applied to account for the repeated measurements within each treatment period of the crossover design.", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.79", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.07", "ciPctValue": "95", "ciLowerLimit": "-0.56", "ciUpperLimit": "0.43", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.24", "estimateComment": "The comparison represents the difference between Arg/Arg and Gly/Gly participants based on the change between placebo salmeterol and active salmeterol for EBC."}]}, {"type": "SECONDARY", "title": "Methacholine Provocative Concentration 20 (PC20)", "description": "Change between placebo salmeterol and active salmeterol for methacholine PC20", "populationDescription": "An ITT paradigm was invoked in which the available data (without any imputation for missing data) on all randomized participants were included.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "milligrams per milliliter", "timeFrame": "Clinic visits at weeks 0 and 18 of each treatment period", "groups": [{"id": "OG000", "title": "B16 Arg/Arg", "description": "B16 Arg/Arg genotype Sequence 1: inhaled salmeterol + inhaled beclomethasone HFA, followed by inhaled placebo salmeterol + inhaled beclomethasone HFA Sequence 2: inhaled placebo salmeterol + inhaled beclomethasone HFA, followed by inhaled salmeterol + inhaled beclomethasone HFA"}, {"id": "OG001", "title": "B16 Gly/Gly", "description": "B16 Arg/Arg genotype Sequence 1: inhaled salmeterol + inhaled beclomethasone HFA, followed by inhaled placebo salmeterol + inhaled beclomethasone HFA Sequence 2: inhaled placebo salmeterol + inhaled beclomethasone HFA, followed by inhaled salmeterol + inhaled beclomethasone HFA"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "42"}, {"groupId": "OG001", "value": "45"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.06", "lowerLimit": "-0.60", "upperLimit": "0.71"}, {"groupId": "OG001", "value": "-1.27", "lowerLimit": "-1.87", "upperLimit": "-0.66"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "A mixed-effects linear model was applied to the base-2 logarithm of the methacholine PC20 to account for the repeated measurements within each treatment period of the crossover design.", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.004", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "1.32", "ciPctValue": "95", "ciLowerLimit": "0.43", "ciUpperLimit": "2.21", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.45", "estimateComment": "The comparison represents the difference between Arg/Arg and Gly/Gly participants based on the change between placebo salmeterol and active salmeterol for methacholine PC20."}]}, {"type": "SECONDARY", "title": "Asthma Control Questionnaire (ACQ)", "description": "Change between placebo salmeterol and active salmeterol for ACQ, where ACQ ranges from 0 (best asthma control) to 6 (worst asthma control).", "populationDescription": "An ITT paradigm was invoked in which the available data (without any imputation for missing data) on all randomized participants were included.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "units on a scale", "timeFrame": "Clinic visits at weeks 0 and 18 of each treatment period", "groups": [{"id": "OG000", "title": "B16 Arg/Arg", "description": "B16 Arg/Arg genotype Sequence 1: inhaled salmeterol + inhaled beclomethasone HFA, followed by inhaled placebo salmeterol + inhaled beclomethasone HFA Sequence 2: inhaled placebo salmeterol + inhaled beclomethasone HFA, followed by inhaled salmeterol + inhaled beclomethasone HFA"}, {"id": "OG001", "title": "B16 Gly/Gly", "description": "B16 Arg/Arg genotype Sequence 1: inhaled salmeterol + inhaled beclomethasone HFA, followed by inhaled placebo salmeterol + inhaled beclomethasone HFA Sequence 2: inhaled placebo salmeterol + inhaled beclomethasone HFA, followed by inhaled salmeterol + inhaled beclomethasone HFA"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "42"}, {"groupId": "OG001", "value": "45"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.13", "lowerLimit": "-0.06", "upperLimit": "0.32"}, {"groupId": "OG001", "value": "0.11", "lowerLimit": "-0.04", "upperLimit": "0.26"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "A mixed-effects linear model was applied to account for the repeated measurements within each treatment period of the crossover design.", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.89", "statisticalMethod": "Mixed Models Analysis", "paramType": "Mean Difference (Final Values)", "paramValue": "0.02", "ciPctValue": "95", "ciLowerLimit": "-0.23", "ciUpperLimit": "0.26", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.12", "estimateComment": "The comparison represents the difference between Arg/Arg and Gly/Gly participants based on the change between placebo salmeterol and active salmeterol for ACQ."}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "1 year", "description": "does not differ from clinicaltrials.gov definitions", "eventGroups": [{"id": "EG000", "title": "B16 Arg/Arg", "description": "B16 Arg/Arg genotype Sequence 1: inhaled salmeterol + inhaled beclomethasone HFA, followed by inhaled placebo salmeterol + inhaled beclomethasone HFA Sequence 2: inhaled placebo salmeterol + inhaled beclomethasone HFA, followed by inhaled salmeterol + inhaled beclomethasone HFA", "seriousNumAffected": 1, "seriousNumAtRisk": 42, "otherNumAffected": 20, "otherNumAtRisk": 42}, {"id": "EG001", "title": "B16 Gly/Gly", "description": "B16 Arg/Arg genotype Sequence 1: inhaled salmeterol + inhaled beclomethasone HFA, followed by inhaled placebo salmeterol + inhaled beclomethasone HFA Sequence 2: inhaled placebo salmeterol + inhaled beclomethasone HFA, followed by inhaled salmeterol + inhaled beclomethasone HFA", "seriousNumAffected": 4, "seriousNumAtRisk": 45, "otherNumAffected": 20, "otherNumAtRisk": 45}], "seriousEvents": [{"term": "hospitalization", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 42}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 45}]}, {"term": "hospitalization", "organSystem": "Psychiatric disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 42}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 45}]}], "otherEvents": [{"term": "respiratory infection", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 100, "numAffected": 20, "numAtRisk": 42}, {"groupId": "EG001", "numEvents": 98, "numAffected": 20, "numAtRisk": 45}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "The study used a moderately high dose of ICS. Genotype-specific effects may be evident at lower doses of ICS often used in combination therapy. Also, short-acting \u03b22-agonists have been shown to have genotype-specific effects on asthma outcomes."}, "certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Vernon M. Chinchilli", "organization": "Penn State College of Medicine", "email": "vchinchi@psu.edu", "phone": "717-531-4262"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000001507", "term": "Beclomethasone"}, {"id": "D000068299", "term": "Salmeterol Xinafoate"}], "ancestors": [{"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000005938", "term": "Glucocorticoids"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}], "browseLeaves": [{"id": "M4800", "name": "Beclomethasone", "asFound": "Domains", "relevance": "HIGH"}, {"id": "M251", "name": "Salmeterol Xinafoate", "asFound": "Metabolism", "relevance": "HIGH"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M9047", "name": "Glucocorticoids", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}